Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Pharmaceutical and Bioengineering Advances in Medicine
share announcement

Pharmaceutical and Bioengineering Advances in Medicine

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 10181

Special Issue Editors

Dr. Vinu Krishnan

E-Mail Website
Guest Editor
Intellia Therapeutics, Inc., 40 Erie St., Cambridge, MA, USA
Interests: nanomedicine; drug delivery; non-viral gene delivery; cell-based drug delivery; hydrogels; formulation science and analytical development
Dr. Anusha Pusuluri

E-Mail Website
Guest Editor
Kala Pharmaceuticals, 490 Arsenal Way, Suite 120, Watertown, MA, USA
Interests: drug delivery; formulations; nanomedicine; bioengineering
Dr. Zongmin Zhao

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA
Interests: drug delivery; biomaterials; nanomedicine; cell therapy; immunotherapy

Special Issue Information

Dear Colleagues,

As Guest Editors of this issue of Pharmaceutics, we invite researchers to submit their original high-quality publications covering current research activities and advancements in the areas of Pharmaceutical Science and Bioengineering that pertain to medicine. We are particularly interested in state-of-the-art efforts that focus on improving drug delivery (topical, oral, intravenous, sublingual, inhalation, ocular, etc.), nonviral gene delivery, cell therapies, and immune engineering. The issue aims to capture the latest knowledge on how structure/compositional/functional activity relationships of the payload and its delivery system could improve clinical efficacy. We also intend to include recent approaches in manipulating living cells as therapies and discuss challenges associated with its manufacturing and regulatory approval. Under immune engineering, the focus will be on materials that have demonstrated potential in harnessing the immune system to diagnose and/or treat diseases. Articles prepared as research papers, reviews and short communications are welcome for publication.

Dr. Vinu Krishnan
Dr. Anusha Pusuluri
Dr. Zongmin Zhao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomaterials
  • nanoparticles
  • hydrogels
  • drug delivery
  • gene delivery
  • cell therapies
  • cellular engineering
  • immune engineering

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 4707 KiB  
Article
Biodegradable Carbonate Apatite Nanoparticle as a Delivery System to Promote Afatinib Delivery for Non-Small Cell Lung Cancer Treatment
by Nian N. N. Maarof, Emilia Abdulmalek, Sharida Fakurazi and Mohd Basyaruddin Abdul Rahman
Pharmaceutics 2022, 14(6), 1230; https://doi.org/10.3390/pharmaceutics14061230 - 10 Jun 2022
Cited by 4 | Viewed by 2460
Abstract
Nanomedicine-based drug-delivery systems have significant interest in cancer treatment, such as improving the stabilities and biocompatibilities, precise targeting, and reducing toxicities for non-cancerous cells. Herein, this study presents the synthesis and characterisation of carbonate apatite nanoparticles (nCA) and encapsulated afatinib (AFA) as promising [...] Read more.
Nanomedicine-based drug-delivery systems have significant interest in cancer treatment, such as improving the stabilities and biocompatibilities, precise targeting, and reducing toxicities for non-cancerous cells. Herein, this study presents the synthesis and characterisation of carbonate apatite nanoparticles (nCA) and encapsulated afatinib (AFA) as promising drug delivery candidates for lung cancer treatment. nCA/AFA was synthesised and physicochemically characterised, then the encapsulation capacity, drug loading, and cumulative drug release profile were evaluated. Powder X-ray diffraction (PXRD) confirmed that the synthesised nCA is apatite. Fourier-transform infrared spectroscopy (FTIR) results confirmed the drug loading into the nanoparticles. High-resolution transmission electron microscopy (HR-TEM) determined the morphology of nCA and nCA/AFA and the diameters of 47.36 ± 3.16 and 42.97 ± 2.78 nm, respectively, without an unaltered nCA phase. Encapsulation efficiency (%) and drug loading (%) were 55.08% ± 1.68% and 8.19% ± 0.52%. Brunauer–Emmett–Teller (BET) and dynamic light-scattering (DLS) results revealed that the synthesised nCA is mesoporous, with a surface area of 55.53 m2/g, and is negatively charged. Atomic force microscopy (AFM) showed increasing roughness of nCA/AFA compared to nCA. The drug release from the nano-formulation nCA/AFA demonstrated slow and sustained release compared to the pure drug. Accordingly, nCA/AFA represents a promising drug delivery system for NSCLC treatment. Full article
(This article belongs to the Special Issue Pharmaceutical and Bioengineering Advances in Medicine)
►▼ Show Figures

Figure 1

14 pages, 1740 KiB  
Article
Characterization of Drug Release from Mesoporous SiO2-Based Membranes with Variable Pore Structure and Geometry
by Frank Baumann, Theresa Paul, Susan Wassersleben, Ralf Regenthal, Dirk Enke and Achim Aigner
Pharmaceutics 2022, 14(6), 1184; https://doi.org/10.3390/pharmaceutics14061184 - 31 May 2022
Cited by 2 | Viewed by 1542
Abstract
Transdermal drug delivery systems (TDDSs) play important roles in therapy due to distinct advantages over other forms and types of drug application. While common TDDS patches mainly consist of polymeric matrices so far, inorganic carriers show numerous advantages such as high mechanical stability, [...] Read more.
Transdermal drug delivery systems (TDDSs) play important roles in therapy due to distinct advantages over other forms and types of drug application. While common TDDS patches mainly consist of polymeric matrices so far, inorganic carriers show numerous advantages such as high mechanical stability, possible re-use and re-loading of drugs, and a broad chemical compatibility with therapeutically relevant compounds and chemical enhancers. Mesoporous glasses can be prepared in different monolithic shapes, and offer a particularly wide range of possible pore volumes, pore diameters, and specific surface areas. Further, they show high loading capacities and favorable physical, technical, and biological properties. Here, we explored for the first time monolithic SiO2-based carriers as sustained release systems of therapeutic drugs. In an ideally stirred vessel as model system, we systematically analyzed the influence of pore diameter, pore volume, and the dimensions of glass monoliths on the loading and sustained release of different drugs, including anastrozole, xylazine, imiquimod, levetiracetam, and flunixin. Through multilinear regression, we calculated the influence of different parameters on drug loading and diffusion coefficients. The systematic variation of the mesoporous glass properties revealed pore volumes and drug loading concentrations, but not pore diameter or pore surface area as important parameters of drug loading and release kinetics. Other relevant effectors include the occurrence of lateral diffusion within the carrier and drug-specific properties such as adsorption. The structure–property relationships derived from our data will allow further fine-tuning of the systems according to their desired properties as TDDS, thus guiding towards optimal systems for their use in transdermal drug applications. Full article
(This article belongs to the Special Issue Pharmaceutical and Bioengineering Advances in Medicine)
►▼ Show Figures

Figure 1

20 pages, 7656 KiB  
Article
Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma
by Vinu Krishnan, Vimisha Dharamdasani, Shirin Bakre, Ved Dhole, Debra Wu, Bogdan Budnik and Samir Mitragotri
Pharmaceutics 2022, 14(2), 466; https://doi.org/10.3390/pharmaceutics14020466 - 21 Feb 2022
Cited by 6 | Viewed by 3058
Abstract
Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two [...] Read more.
Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two chemotherapeutic agents—doxorubicin (DOX) and camptothecin (CPT)—were incorporated and tested for their synergistic potency against a broad panel of blood-cancer cell lines. The pair also demonstrated the ability to achieve immunogenic cell death by increasing the surface exposure levels of Calreticulin, thereby highlighting its ability to induce apoptosis via an alternate pathway. Global proteomic profiling of cancer cells treated with HA–DOX–CPT identified pathways that could potentially predict patient sensitivity to HA–DOX–CPT. This lays the foundation for further exploration of integrating drug delivery and proteomics in personalized immunogenic chemotherapy. Full article
(This article belongs to the Special Issue Pharmaceutical and Bioengineering Advances in Medicine)
►▼ Show Figures

Figure 1

19 pages, 2213 KiB  
Article
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
by Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund and Anna Orlova
Pharmaceutics 2021, 13(11), 1974; https://doi.org/10.3390/pharmaceutics13111974 - 21 Nov 2021
Cited by 6 | Viewed by 2444
Abstract
Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of [...] Read more.
Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1. Full article
(This article belongs to the Special Issue Pharmaceutical and Bioengineering Advances in Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop